Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL... Selecta Biosciences Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others. Show more
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.8 | 16.9799878714 | 16.49 | 20.12 | 16.4 | 82172 | 18.00920832 | CS |
4 | 0.33 | 1.74050632911 | 18.96 | 20.295 | 16.4 | 132402 | 18.26351611 | CS |
12 | -2.81 | -12.7149321267 | 22.1 | 26.5 | 15.5 | 126171 | 19.11993077 | CS |
26 | 1.29 | 7.16666666667 | 18 | 26.5 | 12.48 | 111003 | 18.30657212 | CS |
52 | -9.06 | -31.9576719577 | 28.35 | 41.87 | 11.665 | 239542 | 19.72791679 | CS |
156 | -4.905 | -20.272783633 | 24.195 | 42.6 | 11.665 | 359838 | 22.60572957 | CS |
260 | -4.905 | -20.272783633 | 24.195 | 42.6 | 11.665 | 359838 | 22.60572957 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales